Hepatocyte growth-promoting factor (pHGF) has the greatest potential as a therapeutic agent for vascular growth factor. The aim of this study was to investigate the effect of pHGF on myocardial ischemia and exercise capacity in patients with severe coronary artery disease (CAD).
artery bypass surgery, and the effect of medication is poor.
1) The prognosis of this kind of patient is directly related to the formation of collateral arteries and their compensation capability. However, the connection between the formation of collateral arteries in CAD and humoral and cellular factors has not yet been well established.
2) Animal experiments in recent years have showed hepatocyte growth factor (HGF) can exclusively stimulate the growth of endothelial cells, and promote repair of blood vessels and collateral circulation in ischemic areas, acting as a "molecular coronary artery bypass". In addition, it plays an important role in myocardial preservation to reduce the apoptosis of myocardial cells, so it is believed to be the therapeutic agent having the greatest potential as a vascular growth factor. 3, 4) Although favorable outcomes for HGF treatment have already been obtained in CAD in an animal empirical study, clinical studies are relatively few due to restrictions on methods with which to evaluate the therapeutic effects. 5) Hepatocyte growth-promoting factor (pHGF) is a mixture extracted from infant-pig (0 to 2 months of age) liver, and is mainly composed of macromolecular protein and micromolecule polypeptide, polynucleotide, and some HGF, and its total molecular weight is about 15 kD. 6, 7) pHGF developed in China has been extensively used clinically to treat hepatic disease for many years, however, no studies have investigated the effects of pHGF in treating CAD. The objective of the present study was to investigate the effect of pHGF on myocardial ischemia during exercise and exercise capacity on the basis of standard medication in patients with severe CAD.
Methods
Patients: A double-blind, prospective, randomized, controlled single-center study was conducted to investigate the effects of pHGF on myocardial ischemia and exercise capacity in patients with severe CAD. Forty-nine patients with severe CAD diagnosed by coronary angiography were enrolled and randomized into a pHGF group (21 subjects) and a control group (28 subjects) according pHGF infusion (2 mg/kg, once a day for two weeks, from Dari Biochemistry Medicine Industry Inc, Guangdong Province, China) or saline infusion (250 mL, once a day for two weeks) between January 2004 and December 2006. All patients were treated on the basis of standard medication [Aspirin or clopidogrel, nitrate, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), β-receptor blocker, Ca 2+ channel blocker, statins, and so on]. No patient used heparin or low molecular weight heparin during the study period, or undertook any exercise or rehabilitation. Enrollment criteria included severe CAD (defined as severely diffusing lesions of 3 coronary arteries, severe EFFECT OF PHGF ON MYOCARDIAL ISCHEMIA injury to a tiny, distal artery, stenosis ≥ 70%), age ≤ 70 years old, and LVEF ≥ 35%. Exclusion criteria included myocardial infarction within the last 3 months, unstable angina pectoris, unstable congestive heart failure, severe arrhythmia, age > 70 years old, uncontrolled high blood pressure or diabetes, lower extremity arteriosclerosis, hepatic, kidney, lung, or thoracic disease, an infectious disease, tumor, hematological system disease, any disease which may have affected the treadmill graded exercise test, or undertaking any exercise training and/or rehabilitation in the preceding 6 months. This study was approved by the Ethics Committee of The First People's Hospital of Hangzhou. All subjects signed informed consent forms prior to undergoing any examination or treatment.
Reactions to medicines: Any allergic response, adverse effect, or aggravation of a primary disease, including acute myocardial infarction, acute heart failure, or other severe complication was recorded during the study. Cardiopulmonary exercise test: Cardiopulmonary exercise testing (CPET) was performed before and after pHGF treatment. CPET was performed on a treadmill (SENSORMEDICS) with progressive increments in 3-minute stages according to a modified Bruce protocol under continuous and simultaneous monitoring of a 12-lead electrocardiogram, blood pressure, breath-by-breath expired gas, and finger blood oxygen saturation (SaO 2 ). Treadmill graded exercise testing was conducted by special technicians who were blinded to the angiographic and clinical data. The patients were encouraged to exercise until reaching a sub-maximal exercise standard, defined as a heart rate reaching 85% of their predicted maximal heart rate or VO 2 reaching 25 L/min.kg at an RER > 1.1. The exercise was stopped when the subject experienced intolerable symptoms, such as breathlessness, arterial pulse SaO 2 ≤ 80%, and systolic blood pressure > 250 mmHg, diastolic blood pressure >115 mmHg, or hypotension, or when the electrocardiogram indicated that the criteria for ending the test were met. A positive response on electrocardiography was considered to be 1 mm of horizontal or downsloping ST depression in 3 consecutive beats compared with those of the electrocardiogram at rest. An upsloping ST depression of 1.5 mm below the baseline at 0.08 seconds after the J point, or severe ventricular arrhythmia or second or third degree atrioventricular block were considered positive. 8) CPET parameters obtained included total exercise time, HRmax, degree of depressed ST segment, HRmax/ST, total exercise time/ST, total work, and SBP at peak exercise. HRmax was defined as the heart rate of a patient when reaching submaximal exercise standard or the max heart rate a patient can tolerate when undergoing the treadmill graded exercise test. HRmax/ST is the maximum heart rate when the ST segment was depressed 1 mm, reflecting the capability to tolerate myocardial ischemia. Total exercise time/ST is the time that ST segment depression of 1 mm is needed, reflecting the exercise tolerance of the patients.
Echocardiograms: Left ventricular structure and cardiac function were measured before and after two weeks of pHGF treatment using a Philips SONOS-7500 color Doppler flow imaging meter which has a feeler frequency of 2-4 MHz. All measured indexes are presented as the average of 3 continuous cardiac cycles. Left ventricular ejection fraction (LVEF) was measured by the Simpson method. Measurement of serum HGF levels: Peripheral blood was withdrawn and centrifuged for 15 minutes at 3500 RPM in the first 24 hours before and two weeks after pHGF treatment. Blood serum was stored at -70°C. The levels of serum HGF (assay kit purchased from Research & Diagnostics Systems, Inc., Minneapolis, Minnesota, USA) were measured by enzyme-linked immunosorbent assay (ELISA). Statistics: Measurement data are presented as the mean ± standard deviation. Parameters between before and after treatment were compared with the paired t-test, while those between two groups were compared with the unpaired t-test. Numerical data were compared with the chi-square test. A P < 0.05 indicates a statistically significant difference.
Results

Patient characteristics:
The patient characteristics are summarized in Table I . The pHGF group and control group were comparable with respect to age, gender, and cardiovascular risk factors including smoking, diabetes, hypertension, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, In the pretreatment examination, the pHGF group showed no statistically significant difference in serum HGF level compared with the control group. Serum levels of HGF were elevated significantly after pHGF treatment, however, there was no change in the control group (Table II) . CPET and LVEF results: Submaximal exercise standard during treadmill graded exercise testing before intervention (P = 0.553) was attained in 14 (67%) patients in the pHGF group and in 18 (64%) patients in the control group. However, more patients in the pHGF group reached the submaximal exercise standard [19 (90%) and 18 (64%), respectively, P = 0.035]. There were no differences in the parameters of CPET and LVEF (P > 0.05) between the pHGF group and control group before the pHGF intervention. Total exercise time, systolic blood pressure in the peak of exercise, total exercise time/ST, and total work were all increased in both groups after intervention (all P < 0.05). Furthermore, total exercise time and total work were increased more significantly in the pHGF group than in the control group (Table III) . The degree of exercise-induced ST segment depression after pHGF treatment was decreased more significantly than before intervention [P = 0.01] in the pHGF group, but there were no changes in the control group. Similar results were also found for HR-max and HRmax/ST. There was no difference in LVEF between the groups (Table III) .
Discussion
The incidence of various cardiac events is fairly high and the prognosis is extremely poor because of the lack of effective treatments for patients with severe CAD. Various degrees of collateral circulation are formed naturally in most patients with CAD, however, it is always difficult to satisfy the blood flow requirements of normal myocardium with collateral circulation. Therefore, it is important to investigate the effect of medication at promoting the neogenesis of blood vessels in order to improve the blood supply to ischemic myocardium, cardiac function, and prognosis with the aim of directly improving and reestablishing the collateral circulation. HGF may become an effective method for treating severe CAD. 9, 10) HGF, which has a molecular weight of 82-85 KD and genic length of 70 Kb, is a recently discovered species of vascular growth factor and is a kind of multifunctional factor derived from mesenchyma. It is a heterodimer, consisting of a 69 KD alpha chain and 34 KD beta chain held together by a single disulfide bond. HGF has various functions and high affinity to heparin. In recent years, animal studies have suggested that HGF had a marked effect on repairing tissue and stimulating mitosis of blood vessel endothelium after bonding its specific receptor called c-METO.
11,12) Nakamura, et al found that HGF could decrease myocardial cell apoptosis and the areas of infarction in mice with ischemia/ reperfusion injury, while neutralizing HGF antibody increased the areas of EFFECT OF PHGF ON MYOCARDIAL ISCHEMIA infarction and the case fatality rate caused by cardiac failure. 13) Ahmet, et al discovered that perfusion of ischemic myocardium was improved, the areas of ischemic myocardium were decreased, and capillary density was increased after gene transfer of HGF in canine heart.
14) The level of peripheral serum HGF had a close correlation with the degree and prognosis of atherosclerosis. 15, 16) Although pHGF can not be used clinically to treat any cardiovascular disease, its effects on viral hepatitis, tumors, cardiovascular disease, and neuroprotective activity have been intensively investigated in recent years. pHGF approved by China's State Food and Drug Administration (SFDA) has been extensively used clinically in China to treat hepatic disease for nearly 20 years, but no studies have investigated the effects of pHGF on CAD. 17) pHGF is a bioactive micromolecular substance which can promote the regeneration, mitosis, and growth of human and animal cells. Many countries around the world have conducted research on pHGF. It is a crude, unpurified extract that may contain a specific hepatocyte growth stimulant or HGF.
18) The results of the present study indicate that the level of serum HGF was elevated in patients with CAD after two weeks of treatment with pHGF. Possible explanations may be 1) the pHGF used in this study contained some HGF, or 2) pHGF possibly promoted the liberation or synthesis of endogenous HGF in humans.
At present, the main remaining drawback is the lack of a suitable method with which to evaluate the neogenesis of blood vessels in a clinical study involving molecular coronary artery bypass. Medication, coronary angiography, and echocardiograms can evaluate compensatory coronary artery circulation, but they can not assess the effect on cardiopulmonary functional capacity after the establishment of coronary artery collateral microcirculation, especially the effect on coronary artery reserve. Therefore, this study first applied treadmill graded exercise testing to evaluate the coronary artery reserve before and after treatment with pHGF in severe CAD. All patients in this study underwent echocardiograms before and after intervention. The results showed there were no significant changes in LVEF before and after treatment with pHGF, which is probably related to the fact that routine echocardiograms are not very sensitive at determining cardiac reserve. At the same time, the results showed that an improvement in resting cardiac function before and after treatment with pHGF was not obvious, but resting cardiac function does not reflect the cardiac reserve of patients. Evaluation of cardiac reserve likely has greater clinical value. [19] [20] [21] Recovery cardiopulmonary index is important for the evaluation of patients with CAD and may differ functionally according to the degree of the disease. Thus, additional recovery index measurements are recommended for standard CPET for more intensive and quantitative assessment of at least the functional degree of CAD, which seems to correlate well with the anatomical findings of the coronary angiogram. CPET can reflect cardiac coronary reserve during exercise and has been extensively used to evaluate the exercise capacity of cardiac disease patients and severity of myocardial ischemia. 22) Our results indicate that exercise capacity indexes, such as total exercise time, systolic blood pressure in the peak of exercise, total exercise time/ST, and total work were improved significantly in both groups treated on the basis of standard medication. Furthermore, they showed that the total exercise time and total work were increased even more significantly in the pHGF group than in the control group. The degrees of ST segment depression during exercise, HR-max, and HRmax/ST were improved significantly in the pHGF group after treatment, but were not improved in the control group, which might be one of the effects of pHGF on the improvement of coronary reserve and exercise capacity of CAD patients.
The limitations of the study include the small cohort of patients, and because the sample size was small and the investigative cycle was short, various issues remain to be clarified, such as the relationship between the therapeutic effect and dosage of pHGF treatment, connection between the therapeutic effect and time of therapy, and long-term efficacy and safety, all of which need further investigation. Conclusions: The levels of HGF increased significantly after pHGF treatment in patients with severe CAD. pHGF could favorably improve exercise-induced myocardial ischemia and enhance exercise capacity on the basis of standard medication in patients with severe CAD.
